k 2023

The role of endoplasmic reticulum stress on immune surveillance and the effectiveness of immunotherapy in treatment of ovarian and renal cell carcinoma

MORÁŇ, Lukáš, Barbora VAVRUŠÁKOVÁ, Kateřina VAŠÍČKOVÁ, Lenka KREJČÍ, Kamila SOUČKOVÁ et. al.

Basic information

Original name

The role of endoplasmic reticulum stress on immune surveillance and the effectiveness of immunotherapy in treatment of ovarian and renal cell carcinoma

Authors

MORÁŇ, Lukáš (203 Czech Republic, belonging to the institution), Barbora VAVRUŠÁKOVÁ (203 Czech Republic, belonging to the institution), Kateřina VAŠÍČKOVÁ (203 Czech Republic, belonging to the institution), Lenka KREJČÍ (203 Czech Republic, belonging to the institution), Kamila SOUČKOVÁ (203 Czech Republic, belonging to the institution), Táňa MACHÁČKOVÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Marek SVOBODA (203 Czech Republic, belonging to the institution)

Edition

12th International Conference Analytical Cytometry, 2023

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30204 Oncology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/23:00134716

Organization unit

Faculty of Medicine

Keywords in English

ovarian cell carcinoma; renal cell carcinoma; endoplasmic reticulum stress
Změněno: 29/4/2024 08:54, Mgr. Tereza Miškechová

Abstract

V originále

The role of endoplasmic reticulum stress on immune surveillance and the effectiveness of immunotherapy in treatment of ovarian and renal cell carcinoma - conference abstract.

Links

NU21-03-00539, research and development project
Name: Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu
Investor: Ministry of Health of the CR, The effect of endoplasmic reticulum stress on the immune status of tumors and the efficiency of immunotherapy in the treatment of ovarian and renal cell carcinoma, Subprogram 1 - standard